New eye injection could mean fewer doctor visits for wet AMD patients
Disease control
Completed
This phase 2 trial tested a new drug called EYP-1901, given as an eye injection, for people with wet age-related macular degeneration (AMD). The goal was to see if it works as well as the standard treatment, aflibercept (Eylea), but with fewer injections. 161 participants receive…
Phase: PHASE2 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC